Search PubMed⌕ Search

Biomedical subjects

M Blum

Publications and source records attributed to M Blum.

At least 91 records · Page 5Linked to original sources
PubMed1998

[Flare measurement and albuminuria in type I diabetics].

BACKGROUND: Chronic hyperglycaemia causes microangiopathy with manifestations in different organ systems. The purpose of this study was to investigate whether anterior chamber protein concentrations and albuminuria in patients with diabetes mellitus type 1 have any correlation. PATIENTS AND METHODS: 23 patients with type 1 diabetes were examined in both eyes by the use of the laser flare-cell meter (LFCM). After clinical exclusion of urinary tract infection urine-samples were taken on the examination-day. Patients were divided into two groups: group 1 consisted of 13 patients with albuminuria (8x microalbuminuria, 5x macroalbuminuria), group 2 comprised 10 controls with normal urine albumin concentrations. RESULTS: Both groups were identical according to age and gender. The flare values in the group with albuminuria were significantly elevated (10.7 +/- 7.1 counts/msec) in comparison to those of the control group (3.7 +/- 1.9 counts/msec)(p = 0.042). The duration of the diabetes was as well significantly different in both groups (7.9 +/- 6.9 yrs. vs. 23.9 +/- 13.4 yrs.)(p = 0.02). A correlation was found between albuminuria and flare values (r = 0.67; p = 0.003). CONCLUSIONS: Our results demonstrate a correlation between protein concentration in aqueous and albuminuria. In future flare measurements could possibly offer a non-invasive diagnosis of diabetic nephropathy.

Adult↗
PubMed1998

Comparison of a vegetable-based (soya) and an animal-based low-protein diet in predialysis chronic renal failure patients.

There is some experimental evidence to suggest that progression of chronic renal failure (CRF) is slower on diets based on soya protein than on diets based on animal protein. We have compared the effect of a soya-based vegetarian low-protein diet (VPD) and an animal-based low-protein diet (APD) in 15 patients with CRF. 15 patients with CRF (51Cr-EDTA-measured glomerular filtration rate 15-50 ml/min/1.73 m2) were studied. In a randomized crossover trial, the patients were given each diet (each containing 0.75 g protein and 32 kcal per kilogram body weight) for a 6-month period. Nine patients completed the trial, 2 others dropped out because they could not tolerate the VPD, 3 because of unrelated medical complications, and 1 for technical reasons. The caloric intake was higher and the protein, phosphate and essential amino acid intake lower on the VPD than on the APD. The compliance with the suggested caloric intake was better with the VPD than with the APD (97 vs. 88% of recommended intake), as was the compliance with the suggested protein intake (94 vs. 112% of recommended intake) and with the suggested phosphate intake (102 vs. 116%). The mean glomerular filtration rate, as judged by 51Cr-EDTA, was similar after 6 months on each diet and remained unchanged throughout the entire year of the study. The rate of fall of glomerular filtration, as measured by the slope of 1/serum creatinine was slowed by 73% during the 1-year study period as compared with the prestudy period. Nutritional status (as measured by body mass index, midarm circumference, and lean body mass and percent body fat), serum transferrin, cholesterol and albumin, and total lymphocyte count were similar on the two diets. The serum albumin level on both diets, however, was significantly higher on the two diets than during the prediet period. Blood urea nitrogen, urine urea nitrogen, protein catabolic rate, and 24-hour urine creatinine and phosphate were lower on the VPD than on the APD. The 24-hour protein excretion was similar on the two diets. The two low-protein diets resulted in a slowing in the progression of CRF. A VPD is well tolerated in CRF and is associated with lower protein and phosphate intakes and a higher caloric intake than an APD and may, therefore, be used as a safe alternative or partial substitute for the usual APD in CRF.

Adult↗
PubMed1998

Low nitric oxide production in patients with chronic renal failure.

BACKGROUND: Rats with chronic renal failure have a low nitric oxide (NO) production and a diminished NO excretion. The supplementation of L-arginine has an inhibitory effect on the progression of renal insufficiency. METHODS: The present study was designed to determine whether chronic renal failure patients have a low NO production. Plasma and urine nitrate (NO3) and nitrite (NO2), stable metabolites of NO, were measured in 83 consecutive patients with chronic renal failure. The 83 chronic renal failure patients were divided into three groups: group 1, mild renal failure (creatinine clearance >60 ml/min/1.73 m2); group 2, moderate renal failure (creatinine clearance >30 <60 ml/min/1.73 m2), and group 3, severe renal failure (creatinine clearance <30 ml/min/1.73 m2). Thirty-three healthy volunteers served as controls. RESULTS: The daily urinary NO excretion was significantly lower in patients with moderate and severe renal failure as compared with those with mild renal failure and normal controls. The lowest values were found in the severe renal failure group. When the 24-hour urinary NO excretion or NO per milligram creatinine and the NO clearance were correlated with the renal function in all patients as a group, these parameters were directly correlated with the creatinine clearance and inversely correlated with the serum creatinine level. The plasma NO concentration was not different between the three chronic renal failure groups, but higher than in the controls. Plasma NO in renal failure patients was not correlated with the creatinine clearance or serum creatinine levels. CONCLUSIONS: Chronic renal failure is a state of NO deficiency. Treatment strategies to increase NO production (L-arginine supplementation or other NO compounds) may prove to be useful in maintaining the renal function and slow the progression of renal disease.

Aged↗
PubMed1998

Aberrant regulation of bone trace elements in motheaten and osteopetrosis mutant mice.

Increasing numbers of genetic diseases involving bone development and models for these diseases have been identified recently. Analysis of these bone diseases have revealed that regulated action of multiple growth factors and subsequent signal transduction are essential for normal bone formation. In this paper, two murine mutant mice viable motheaten and osteopetrosis are analyzed. Mice with the recessive 'viable motheaten' mutation express a severe immunodeficiency syndrome and bone defects. Mutations at the motheaten locus were shown to be the result of aberrant splicing of the gene encoding hematopoietic cell phosphatase (Hcph). Mice homozygous for the osteopetrosis mutation develop congenital osteopetrosis due to a severe deficiency of osteoclasts. It has been recognized that bone trace element composition analysis helps to define bone-related physiological conditions. We have analyzed bone trace element composition in viable motheaten and osteopetrosis mutant animal models in this study. In order to gain insights into the effects of particular genetic defects on bone trace element composition, inductively coupled plasma atomic emissions spectrometry (ICP-AES) analysis was performed. Marked changes in bone trace element levels were found in limb bones of viable motheaten and osteopetrosis mutant mice. An assessment of these trace element spectrum in the two mutant models with respect to each genetic defects are discussed in this paper.

Animals↗
PubMed1998

[Emissions from building products and investigation of their toxicity with the bioluminescence inhibition test].

The investigation of building products in test chambers contains so far only analytical and sensory measurements. In this paper, first experiments for the direct testing of the acute toxicity of building product emissions with the bioluminescence inhibition test are presented. The test specimen was a solvent-free dispersion paste for gluing carpets. Two tests with different air change rates were performed in a 1 m3 stainless steel test chamber. The emissions were concentrated at uniform timesteps in impinger-bottles and measured with the bioluminescence inhibition test. At the same time the concentrations of the emissions in the test chamber were measured both with charcoal adsorbent tubes (carbon disulphide desorption) and with tenax tubes (thermal desorption). The results of the bioluminescence inhibition test show, that the decrease of the toxicity over a period of 28 days is far lower at a low air change rate than at a higher air change rate. We also found, that from the multitude of the emitted substances the toxicity for the luminescence bacteria was only caused by Ethanol-[2-(2-butoxyethoxy)]-acetate.

Adhesives↗
PubMed1997

Correlation between loss of middle ear bones and altered goosecoid gene expression in the branchial region following retinoic acid treatment of mouse embryos in vivo.

The homeobox gene goosecoid marks the Spemann organizer in vertebrate gastrula embryos, and is expressed in the craniofacial region, body wall and limbs during organogenesis. Mouse mutants of goosecoid displayed a variety of phenotypes related to the expression pattern at mid-embryogenesis. These defects included loss of the tympanic ring and malformation of the malleus, phenotypes which were reminiscent of the teratogenic effects of retinoic acid (RA). Here we investigated the correlation of goosecoid gene expression and RA-teratogenicity following treatment of mouse embryos in vivo at embryonic day (E) 8 + 5 h. We found that goosecoid was specifically affected at E10.5 in branchial arches I and II. Expression was either reduced to background levels or restricted to the branchial cleft region. This change in goosecoid gene expression correlated with a loss of middle ear ossicles and a partial or complete deletion of the tympanic ring, suggesting a role for goosecoid in executing the RA teratogenic effects.

Animals↗
PubMed1997

Nasal and pharyngeal abnormalities caused by the mouse goosecoid gene mutation.

The Goosecoid (gsc) gene is a homeobox-containing gene expressed first in the gastrula, and later during organogenesis in development. The gsc gene transcript is found in the first and second branchial arches, frontonasal mass in its late phase of expression. We have previously shown that targeted mutation of the mouse gsc gene leads to neonatal death and craniofacial defects. In this study, we performed histological studies on craniofacial phenotypes in order to elucidate the processes underlying the neonatal death of gsc mutant mice. We found that gsc mutant mice have aplastic nasal cavities and lack the Sinus Paranasalis. We also showed that secretory olfactory glands in the basal layers are aplastic. This is suggested to be essential defects for olfaction. gsc mutant mice also show several pharyngeal phenotypes, including defects in the pharyngeal muscles and the pharyngeal mucosa. It is therefore suggested that mutant mice develop lethal gastro-intestinal phenotypes caused by defects in breathing and sucking of milk as a consequence of these craniofacial disorders. These results should help elucidating the molecular genetic programs essential to the neonatal development of mammals.

Animals↗
PubMed1997

Protein synthesis-dependent and -independent mechanisms for the regulation of GnRH RNA transcript levels in GT1 cells.

The cellular mechanism for the suppression of GnRH gene expression by the phorbol ester PMA was investigated in GT1 cells. The protein synthesis inhibitor cycloheximide decreased GnRH primary transcript levels, indicating a protein synthesis requirement for basal GnRH transcription. PMA decreased GnRH primary transcript levels even in the presence of cycloheximide, indicating that the PMA suppression of GnRH gene transcription is protein synthesis-independent. In contrast, the PMA-inhibitory effect on GnRH cytoplasmic mRNA levels was significantly reduced or inhibited in the presence of cycloheximide or RNA synthesis inhibitors given within 4 h of PMA, suggesting a protein/RNA synthesis-dependent mechanism for the regulation of GnRH mRNA levels by PMA. Thus, the mechanism for the PMA inhibition of GnRH primary transcript is mediated through a protein and RNA synthesis-independent mechanism, while the decrease in GnRH mRNA levels occurs through a mechanism that involves the induction of new RNA and protein synthesis that happens within 4 h of PMA administration.

Animals↗
PubMed1997

Perinatal asphyxia-induced changes in rat brain tyrosine hydroxylase-immunoreactive cell body number: effects of nicotine treatment.

Perinatal asphyxia (15-22 min) was induced to male Sprague-Dawley rat pups during the last day of gestation and the surviving pups were sacrificed at 4 weeks of age. Brain sections were stained for tyrosine hydroxylase immunoreactivity and Cresyl violet. With increasing duration of perinatal asphyxia a reduction in the number of tyrosine hydroxylase immunoreactive (TH-IR) nerve cell bodies was found in the locus ceruleus, probably reflecting an increased death of noradrenaline nerve cell bodies. In contrast, perinatal asphyxia (15-20 min) resulted in an increased number of TH-IR nerve cell bodies in the A9 (zona compacta of the substantia nigra) and the A10 (ventral tegmental area) regions of the mesencephalon, probably reflecting an increased survival of dopamine nerve cell bodies. Perinatal asphyxia for longer than 20 min periods reduced the number of TH-IR cell bodies in the 4 week old rat, even below those found in control animals, indicating that when asphyxia is induced for a period leading to almost 100% mortality, a long-term reduction of the number of mesencephalic dopamine neurons is produced. It has previously been shown that a 4 week postnatal nicotine (0.2 micromol/kg per h) treatment counteracts the asphyxia-induced increase in TH-IR cell body number in the substantia nigra and ventral tegmental area. Such nicotine treatment did not influence the reduction in TH-IR cell bodies in the locus ceruleus following 15-20 min of perinatal asphyxia.

Animals↗
PubMed1997

Regulation of astroglial-derived dopaminergic neurotrophic factors by interleukin-1 beta in the striatum of young and middle-aged mice.

Interleukin-1 beta (IL-1 beta) can induce dopaminergic axonal sprouting in the denervated striatum of parkinsonian animals. In order to determine whether IL-1 beta effects on dopaminergic axonal sprouting are mediated by the induction of astroglial-derived dopaminergic neurotrophic factors, effects of IL-1 beta treatment on acidic and basic fibroblast growth factor (aFGF and bFGF) and glial cell line-derived growth factor (GDNF) gene expression were examined in primary striatal astrocyte cultures and after in vivo administration. We found a selective induction of bFGF mRNA synthesis but not aFGF or GDNF mRNA after IL-1 beta treatment both in vitro and in vivo. This suggests that bFGF may be the putative endogenous dopaminergic neurotrophic factor mediating lesion-induced plasticity of dopamine neurons. In addition, to determine why recovery from injury becomes reduced with age, we examined whether there was an aging-associated decline in the ability of IL-1 beta to induce the synthesis of neurotrophic factors in middle-aged animals compared to young mice. Interestingly, IL-1 beta stimulated a greater induction in bFGF mRNA levels in the middle-aged mice compared to young mice. These results suggest that the regulation of bFGF and possibly its receptor signaling efficacy may vary as the brain ages.

Age Factors↗
PubMed1997

Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement.

BACKGROUND: Pooled intravenous gammaglobulin (IVIg) was reported to be effective in the treatment of Wegener's granulomatosis (WG). No reports have been made on the effects of this new treatment on ocular manifestations of WG. METHOD: IVIg treatment was given to two patients suffering from WG with ocular involvement after several other treatment regimes had failed. RESULTS: Although the systemic disease was under control, the ocular symptoms of both patients worsened during and after IVIg treatment. In one case an adverse effect consisting of retinal vasculitis was noted on two occasions. CONCLUSION: Although beneficial effects of IVIg treatment on WG have been previously described, the two cases with ocular involvement presented here did not reveal any positive response. Paradoxical and unpredictable reactions cannot be ruled out. Thus, patients treated with IVIg should be closely surveyed by an ophthalmologist.

Adult↗
PubMed1997

[Outcome of cataract operation with reduction of myopia in myopia magna].

UNLABELLED: Patients with high myopia represent a risk group in cataract surgery. They are suspected of having a higher incidence of retina problems after cataract surgery. In addition, IOL calculations may be difficult. METHOD: In a retrospective study data of 97 eyes of 60 high myopic patients were analyzed. The inclusion criterion was an axial length of > 26 mm. All eyes underwent cataract extraction and PC IOL implantation between 1991 and 1995. Evaluation focused on visual outcome, precision of the IOL power calculation and the rate of complications. RESULTS: Visual acuity increased from 0.18 to 0.46 postoperatively. On average, myopia was reduced from -13.6 D to -3.0 D;66% of the patients were +/-1 D;86% were +/-2 D within the predicted calculation of postoperative refraction. During a follow-up period of 14.8 months no retinal detachment occurred. CONCLUSION: Cataract extraction and IOL implantation showed good functional results, and prediction of postoperative refraction was satisfactory. Our data support the studies reporting a low incidence of retinal problems in patients with high myopia.

Aged↗
PubMed1997

[Haptic position of iris-fixed posterior chamber lenses. Determination by ultrasound biomicroscopy].

UNLABELLED: In eyes lacking adequate posterior capsular support, fixation of posterior chamber intraocular lenses (IOL) by iris sutures has become one of the methods available. Ultrasound biomicroscopy (UBM) allows detection of the haptic position postoperatively and determination of its relationship to adjacent intraocular structures. METHODS: Thirteen patients with iris-sutured IOLs were examined pre- and postoperatively with UBM. The examination included locating the haptic and tracing the haptic to the position closest to other uveal structures. RESULTS: The position of all 26 haptics was determined. All haptics were in touch with the iris. In the 12-clock position 11 haptics did not touch other intraocular structures. In one case the haptic was located in the ciliary sulcus, and in another case it touched the ciliary body. In the 6-clock position two haptics were located in the sulcus region, and seven were located posterior to the ciliary processes. Four haptics did not touch any other intraocular structures. CONCLUSIONS: In most cases surgical placement of iris-fixed lenses is a blind procedure. UBM is an adequate method of determining the position of IOL haptics postoperatively.

Aged↗
PubMed1997

[Online measurement of retinal artery branches in type II diabetic patients. Initial clinical trials before and after laser coagulation].

UNLABELLED: By the use of a new online measuring system the effect of argon-laser coagulation in diabetics on the diameters of retinal arteries was measured. METHOD: The vessel diameter of retinal branch arteries were measured in patients with type-II diabetes before and after (0.5 h) argon-laser coagulation. Ten patients without previous laser treatment were included in this study. Measurements were taken in all four quadrants by the use of a new automatic online measuring system. RESULTS: The new technique allowed measurements to be made within an acceptable period of time and with little strain on patients. After argon-laser coagulation 56.7% of retinal arteries showed a significant vasodilation. No significant changes in vessel diameter were found in 18.9% of these arteries, whereas 24.3% showed significant vasoconstriction. CONCLUSION: The new online measuring system is able to measure the effects of photocoagulation on an individual basis with a noninvasive technique. The first findings presented here confirm previous studies of larger groups, with a considerable reduction in efforts required.

Aged↗
PubMed1997

Photographic image analysis system of posterior capsule opacification.

PURPOSE: To describe a morphological scoring system of posterior capsule opacification (PCO) that is not based on visual acuity testing. SETTING: Department of Ophthalmology, University of Heidelberg, Germany. METHODS: Following dilation of the pupil, standardized photographs of the pseudophakic anterior segments were obtained using a photo slitlamp. Posterior capsule opacification was scored by evaluating retroillumination photographs. The individual PCO score was calculated by multiplying the density of the opacification (graded from 0 to 4) by the fraction of capsule area involved behind the intraocular lens (IOL) optic. To evaluate the reliability of the morphological scoring system, six observers examined photographs of five eyes each (Experiment A, interindividual reliability). The same observer scored the PCO in three eyes on five different days (Experiment B, intraindividual reliability). RESULTS: Morphological PCO scores were very reliable. With PCO scoring from 0 to 4, the interindividual reliability showed standard deviations between 0.08 and 0.25. The intraindividual reliability showed standard deviations between 0.06 and 0.19 of the mean individual PCO scores. Standard deviation was 0.12 when different photographs of the same eye were scored. CONCLUSION: The morphological scoring system evaluates the entire area behind the IOL optic and thus includes a larger area of the posterior capsule than does visual acuity testing. The method revealed high reliability and insignificant investigator-dependent variations. When using a standardized photographic setup, systematic errors by the photographic technique were not relevant. This method may be an important tool to accurately test for differences in PCO formation with various IOL styles and surgical methods.

Cataract↗